{
    "symbol": "CERS",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 17:50:08",
    "content": " Examples of forward-looking statements include those related to our future financial and operating results, including our 2022 product revenue guidance and goals, operating expenses, anticipated cash use from operations, gross profits, and gross margins, as well as commercial development efforts, future growth and growth strategy, future product sales, product launches, ongoing and future clinical trials, ongoing and future product development, and our regulatory initiatives, including the timing of these events and activities. We posted third quarter 2022 product revenue of $39.6 million, representing year-over-year growth of 10% led by sales in North America during the quarter. Our third quarter product gross profit was $21.9 million, compared to $18.5 million during the prior year period, an increase of over 18% year-over-year. Moving on, our third quarter operating expenses totaled $36.1 million, roughly in-line with the prior year period and included $5.8 million in non-cash stock based compensation. Our third quarter losses as reported by our non-GAAP adjusted EBITDA were less than half of where they were a year ago and totaled to a negative $2.7 million, compared to a negative $5.6 million during the third quarter of 2021. Year to date losses as reported by our non-GAAP adjusted EBITDA were almost two-thirds lower than the prior year to date total with the 2022 year to date figure totaling to a negative $8.8 million, compared to a negative $25.3 million for the first nine months of 2021."
}